MedTrace Logo

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

NCT04156347 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-10-31

No results posted yet for this study

Summary

This single-arm, non-randomized, dose escalation phase I clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active de novo or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

Conditions

  • Retinoblastoma

Interventions

DRUG

Episcleral Topotecan

Transscleral Topotecan

Sponsors & Collaborators

  • Targeted Therapy Technologies, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2024-10-01
Completion
2024-10-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04156347 on ClinicalTrials.gov